Hikma Pharmaceuticals (OTCMKTS:HKMPF) – Equities research analysts at Jefferies Group raised their FY2022 earnings per share (EPS) estimates for shares of Hikma Pharmaceuticals in a research note issued on Thursday, March 15th, Zacks Investment Research reports. Jefferies Group analyst J. Vane-Tempest now expects that the company will post earnings of $1.21 per share for the year, up from their prior estimate of $1.06. Jefferies Group currently has a “Underperform” rating on the stock.
Other research analysts have also issued research reports about the company. Zacks Investment Research raised Hikma Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 20th. ValuEngine raised Hikma Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company. Hikma Pharmaceuticals has an average rating of “Hold”.
Shares of OTCMKTS:HKMPF opened at $17.10 on Friday. Hikma Pharmaceuticals has a 52-week low of $12.00 and a 52-week high of $25.35. The company has a market capitalization of $4,118.82, a PE ratio of 16.29, a PEG ratio of 6.16 and a beta of -1.09.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/08/equities-analysts-offer-predictions-for-hikma-pharmaceutics-fy2022-earnings-hkmpf.html.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Get a free copy of the Zacks research report on Hikma Pharmaceuticals (HKMPF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.